[go: up one dir, main page]

WO2001021807A8 - Proteine enveloppe 2 (e2) du virus de l'hepatite c qui ne possede pas tout ou partie de la region 1 hypervariable (hvr1), acides nucleiques correspondants, virus chimeriques et utilisation de ces derniers - Google Patents

Proteine enveloppe 2 (e2) du virus de l'hepatite c qui ne possede pas tout ou partie de la region 1 hypervariable (hvr1), acides nucleiques correspondants, virus chimeriques et utilisation de ces derniers

Info

Publication number
WO2001021807A8
WO2001021807A8 PCT/US2000/025987 US0025987W WO0121807A8 WO 2001021807 A8 WO2001021807 A8 WO 2001021807A8 US 0025987 W US0025987 W US 0025987W WO 0121807 A8 WO0121807 A8 WO 0121807A8
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
protein
lacks
hypervariable region
hvr1
Prior art date
Application number
PCT/US2000/025987
Other languages
English (en)
Other versions
WO2001021807A1 (fr
Inventor
Xavier Forns
Jens Bukh
Suzanne U Emerson
Robert H Purcell
Original Assignee
Us Health
Xavier Forns
Jens Bukh
Suzanne U Emerson
Robert H Purcell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Xavier Forns, Jens Bukh, Suzanne U Emerson, Robert H Purcell filed Critical Us Health
Priority to AU76028/00A priority Critical patent/AU7602800A/en
Publication of WO2001021807A1 publication Critical patent/WO2001021807A1/fr
Publication of WO2001021807A8 publication Critical patent/WO2001021807A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24271—Demonstrated in vivo effect

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des molécules d'acide nucléique codant le virus de l'hépatite C, le virus de l'hépatite C chimérique ou la protéine enveloppe 2 du virus de l'hépatite C qui ne possède pas tout ou partie de la région 1 hypervariable de la protéine enveloppe 2. L'invention concerne également l'utilisation de ces molécules d'acide nucléique et leurs polypeptides codés comme vaccins possibles.
PCT/US2000/025987 1999-09-23 2000-09-22 Proteine enveloppe 2 (e2) du virus de l'hepatite c qui ne possede pas tout ou partie de la region 1 hypervariable (hvr1), acides nucleiques correspondants, virus chimeriques et utilisation de ces derniers WO2001021807A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU76028/00A AU7602800A (en) 1999-09-23 2000-09-22 Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15582399P 1999-09-23 1999-09-23
US60/155,823 1999-09-23

Publications (2)

Publication Number Publication Date
WO2001021807A1 WO2001021807A1 (fr) 2001-03-29
WO2001021807A8 true WO2001021807A8 (fr) 2001-10-11

Family

ID=22556944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/025987 WO2001021807A1 (fr) 1999-09-23 2000-09-22 Proteine enveloppe 2 (e2) du virus de l'hepatite c qui ne possede pas tout ou partie de la region 1 hypervariable (hvr1), acides nucleiques correspondants, virus chimeriques et utilisation de ces derniers

Country Status (2)

Country Link
AU (1) AU7602800A (fr)
WO (1) WO2001021807A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1326625A4 (fr) * 2000-09-13 2005-05-04 Hawaii Biotech Inc Composition immunogene de l'hepatite c et procedes d'utilisation de cette derniere
CA2498770C (fr) * 2002-09-13 2015-06-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Pseudo-particules d'hepacivirus infectieuses renfermant des proteines fonctionnelles d'enveloppe e1, e2
EP2366803B8 (fr) 2002-10-16 2015-08-19 Gen-Probe Incorporated Compositions et procédés pour la détection du virus du nil occidental
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
JP2007514413A (ja) 2003-11-12 2007-06-07 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド Ｃ型肝炎ウイルス糖タンパク質をコードする新規配列
EP2061805B1 (fr) 2006-08-25 2020-02-12 Macfarlane Burnet Institute for Medical Research and Public Health Limited Glycoprotéine e2 recombinante du hcv
WO2008125119A1 (fr) 2007-04-13 2008-10-23 Hvidovre Hospital Mutations adaptatives permettant la création de systèmes de culture cellulaire basés sur jfh1 pour le génotype 4a du virus de l'hépatite c
US8945584B2 (en) 2007-04-13 2015-02-03 Hvidovre Hospital Cell culture system of a hepatitis C genotype 3a and 2a chimera
US8618275B2 (en) 2007-05-18 2013-12-31 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 5A
WO2009080052A1 (fr) 2007-12-20 2009-07-02 Hvidovre Hospital Système efficace de culture cellulaire pour le génotype 6a du virus de l'hépatite c
JP2011521985A (ja) * 2008-06-03 2011-07-28 オカイロス アーゲー Ｈｃｖ感染の予防および治療のためのワクチン
US8663653B2 (en) 2008-08-15 2014-03-04 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 2B
US8506969B2 (en) 2008-08-15 2013-08-13 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 7a
EP2344647A1 (fr) 2008-10-03 2011-07-20 Hvidovre Hospital Virus de l'hépatite c exprimant la protéine ns5a marquée par un rapporteur
WO2012075104A2 (fr) * 2010-11-30 2012-06-07 The Trustees Of Columbia University In The City Of New York Nouvel hépacivirus de mammifères non-primates
BR112019018371A2 (pt) * 2017-03-27 2020-04-07 Univ Queensland flavivírus específico para inseto quimérico
CA3178547A1 (fr) * 2020-05-11 2021-11-18 Heidi Drummer Vaccin contre l'hepatite c a base d'acide nucleique comprenant un polypeptide e2 a domaine variable delete

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0697888B1 (fr) * 1993-05-12 2003-09-17 Chiron Corporation Motif conserve de la region e2/ns1 du virus de l'hepatite c
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof

Also Published As

Publication number Publication date
AU7602800A (en) 2001-04-24
WO2001021807A1 (fr) 2001-03-29

Similar Documents

Publication Publication Date Title
WO2001021807A8 (fr) Proteine enveloppe 2 (e2) du virus de l'hepatite c qui ne possede pas tout ou partie de la region 1 hypervariable (hvr1), acides nucleiques correspondants, virus chimeriques et utilisation de ces derniers
WO1999004008A3 (fr) Genomes clones des virus de l'hepatite c infectieuse et leurs utilisations
DK0770679T4 (da) HCV-specifikke peptider, sammensætninger dertil og anvendelse deraf
WO2003048184A3 (fr) Vaccin a sous-unite de ns1 de flavivirus
ATE472335T1 (de) Chimere alphavirus-replikon-partikel
UA85536C2 (en) Viral antigens
WO2003030821A3 (fr) Proteines de fusion d'albumine
PT726955E (pt) Proteinas quimericas compreendendo polipeptidos borrelia: suas utilizacoes
WO2002074807A3 (fr) Immunoadhesines d'erythropoietine de chimpanze (chepo)
WO2004087062A3 (fr) Compositions contenant un virus syncytial respiratoire de la souche 9320 du sous-groupe b, et procedes associes
WO2002027007A3 (fr) Production de vecteurs viraux
AU5322800A (en) Cloned genone of infectious hepatitis c virus of genotype 2a and uses thereof
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof
WO2003006654A3 (fr) Proteines de recombinaison de parapoxvirus ovis et compositions pharmaceutiques issues de celles-ci
DE3853693D1 (de) DNA- und RNA-Moleküle des westlichen Subtyps des FSME-Virus, Polypeptide, die von diesen Molekülen codiert werden, und deren Verwendung.
WO1999004029A3 (fr) Virus de l'hepatite e du porc et ses utilisations
WO2002010417A3 (fr) Procedes et compositions pour la construction et l'utilisation de virus a enveloppe comme particules de presentation
WO2003093431A3 (fr) Reduction de la penetration cellulaire dependante de la molecule d'activation lymphocytaire (slam)
WO2000066743A3 (fr) Vecteurs d'expression virale
WO2001049712A3 (fr) Vaccin destine a la prevention et/ou la prophylaxie de l'anemie infectieuse du saumon chez des poissons
WO2001042299A3 (fr) Virus sentinelle i du virus de l'hepatite (svi)
WO2004087886A3 (fr) Constructions adenovirales e1a modifiees et procedes d'utilisation
WO2000075352A3 (fr) Genomes recombinants vhc/bvdv et utilisation de ceux-ci
PT1383796E (pt) Estirpe neurovirulenta do vírus do nilo ocidental e as suas aplicações

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP